Stock Details
SNY is Sanofi's stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 53.33$. Average daily volumn in 3 months 2.25M. Market cap 138.60B



Stock symbol : SNY. Exchange : NasdaqGS. Currency : USD
Lastest price : 55.50$. Total volume : 1.88M. Market state POST
Click reload if you want to check the lastest price on market!!!

Sanofi (SNY)
Last Price
55.50$
Change
-0.05
Volume
1.88M

Previous Close55.55
Open55.36
Day Range55.27-55.73
Bid55.51 x 1k
Ask55.52 x 1.2k
Volume1.88M
Average Volume2.25M
Market Cap138.6B
Beta0.36
52 Week Range46.93-58.10
Trailing P/E19.60
Foward P/E12.42
Dividend (Yield %)3.19%
Ex-Dividend Date2022-05-26



Financial Details


According to Sanofi's financial reports the company's revenue in 2021 were 39.17B an increase( +5.41%) over the years 2020 revenue that were of 37.37B. In 2021 the company's total earnings were 6.22B while total earnings in 2020 were 12.29B(-50%).


Loading ...



Organization

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines ... for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

Market Cap:
138.60B
Revenue:
39.17B
Total Assets:
120.24B
Total Cash:
10.1B


News about "Sanofi"

longtime-kadmon-consultant-slapped-with-insider-trading-charges-related-to-19b-sanofi-buyout-image

Long­time Kad­mon con­sul­tant slapped with in­sid­er trad­ing charges re­lat­ed to $1.9B Sanofi buy­out

Source from : ENDPOINTS NEWS - 11 hours ago

Months after Sanofi snapped up Kadmon for $1.9 billion, a longtime Kadmon consultant has been accused of using insider knowledge of the buyout to make more than $400,000 in illegal profits. The SEC ...See details»


nice-recommendation-for-sanofi-and-regenerons-cscc-treatment-image

NICE recommendation for Sanofi and Regeneron’s CSCC treatment

Source from : PharmaTimes - 15 hours ago

Libtayo has been approved for adults when curative surgery or radiation is not appropriate The Nationail Institute for Health and Care Excellence (NICE) has published a positive final appraisal ...See details»


Sanofi (NYSE:SNY) Lowered to “Hold” at StockNews.com

Source from : ETF Daily News - 1 days ago

Sanofi (NYSE:SNY – Get Rating) was downgraded by StockNews.com from a “buy” rating to a “hold” rating in a note issued to investors on Wednesday. Separately, UBS Group decreased their target price on ...See details»


sanofi-regenerons-dupixent-gets-fda-nod-for-4th-indication-revised-image

Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication (Revised)

Source from : YAHOO!Finance - 1 days ago

Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.See details»


sanofis-20b-buyout-of-genzyme-pays-off-again-with-european-ok-for-first-niemann-pick-drug-image

Sanofi's $20B buy­out of Gen­zyme pays off again with Eu­ro­pean OK for first Nie­mann-Pick drug

Source from : ENDPOINTS NEWS - 6 days ago

Sanofi CEO Paul Hudson has made clear his intention to develop new rare disease drugs and broaden his company’s offerings. That effort leaped forward on Friday with the EMA's signing off on the compan ...See details»


pay-consultant-charged-with-insider-trades-on-sanofi-kadmon-deal-image

Pay Consultant Charged With Insider Trades on Sanofi-Kadmon Deal

Source from : Bloomberg Law - 2 days ago

The head of an executive pay consulting company in California was accused of trading on confidential information he learned about the acquisition of Kadmon Holdings Inc. by Sanofi SA while working on ...See details»


Global Acetaminophen Market Report to 2031 - Featuring Sanofi, Novartis and Bayer Among Others - ResearchAndMarkets.com

Source from : Associated Press - 11 hours ago

The “Acetaminophen Market” report has been added to ResearchAndMarkets.com’s offering. This report on the acetaminophen market offers a global industry analysis for 2016-2020 and an opportunity ...See details»


sanofi-ordered-to-compensate-french-family-for-epilepsy-drug-side-effects-image

Sanofi ordered to compensate French family for epilepsy drug side effects

Source from : Reuters on MSN.com - 12 days ago

A French court has ordered Sanofi to pay more than 400,000 euros ($416,440) in damages to a family whose child suffered from a form of autism caused by its epilepsy drug Valproate, saying the ...See details»


regeneron-and-sanofis-dupixent-fda-approved-for-eosinophilic-esophagitis-image

Regeneron and Sanofi’s Dupixent FDA-approved for eosinophilic esophagitis

Source from : Outsourcing-pharma - 3 days ago

The approval is the first that the Food and Drug Administration has granted for a drug intended to treat eosinophilic esophagitis, a chronic immune disorder.See details»


Sanofi's Dupixent wins U.S. approval for bigger use

Source from : Reuters - 6 days ago

May 20 (Reuters) - Sanofi (SASY.PA) won expanded U.S. approval for its best-selling Dupixent injection to treat an allergic inflammation of the esophagus, the Food and Drug Administration said on ...See details»


NICE recommends Sanofi and Regeneron’s Libtayo for advanced CSCC

Source from : PMLiVE - 15 hours ago

The National Institute for Health and Care Excellence (NICE) has recommended Sanofi and Regeneron’s Libtayo (cemiplimab) for patients with metastatic or locally advanced cutaneous squamous cell ...See details»


explore-partnering-with-sanofis-vaccines-business-image

Explore partnering with Sanofi’s vaccines business

Source from : Nature - 10 days ago

Roman Chicz, Global Head, External Research and Development, Sanofi, Tel: +1-617-866-4562, Email: [email protected] Donna Martin, Global Head of Business Development, Vaccines Partnering, Sanofi, ...See details»


sanofi-gets-ema-panel-nod-for-enzyme-replacement-therapy-xenpozyme-image

Sanofi gets EMA panel nod for enzyme replacement therapy Xenpozyme

Source from : Seeking Alpha - 6 days ago

A committee of the European Medicines Agency (EMA) recommended the approval of Sanofi' (SNY) enzyme replacement therapy Xenpozyme.The positive opinion by the EMA's Committee ...See details»


Sanofi Receives Another Approval for Blockbuster Drug Dupixent

Source from : Barron's - 5 days ago

Sanofi and Regeneron Pharmaceuticals received yet another approval for their drug Dupixent, this time for a chronic inflammatory disease for which the Food and Drug Administration has never before ...See details»